quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 3, 2026

Spire reaffirms 5%–7% EPS growth target and $11.2B capital plan as Tennessee acquisition nears close

View original at seekingalpha.com
Spire reaffirms 5%–7% EPS growth target and $11.2B capital plan as Tennessee acquisition nears close Earnings Call Insights: Spire Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The storage asset sale process has gone a little longer than we initially anticipated but emphasized continued strong interest

    80% confidence
  • Focus on closing and integrating Tennessee, highlighting scale benefits for customers through shared services

    80% confidence
  • The integration is a significant effort, supported by an 18-month Transition Services Agreement

    80% confidence
  • About $750 million remains to be raised or recycled for the Tennessee acquisition, and any equity market activity would likely occur after the next earnings call

    80% confidence
  • There is an offsetting impact from preferred stock redemption, so net-net, EPS is unchanged

    80% confidence
  • Utilities met all customer obligations during January gas market volatility and hedging strategies performed as expected

    80% confidence
  • Adjusted earnings of $1.77 per share, an increase from $1.34 per share a year ago, attributing the improvement to solid execution in our Gas Utility business, supported by new rates across all of the utilities

    80% confidence
  • Gas Utilities earned $104 million, up $26 million year-over-year, while Gas Marketing and Midstream also contributed positively, partially offset by increased corporate costs and interest expense

    80% confidence
  • Despite extreme conditions, natural gas once again distinguished itself, underscoring that direct use of natural gas remains the most reliable and affordable way to heat your home

    80% confidence
  • The next rate case filing in Missouri is anticipated after fiscal year-end before Thanksgiving

    80% confidence
  • The adjusted earnings range for Corporate and Other was updated to negative $40 million to negative $46 million, lowering the midpoint by $9 million to reflect higher interest expense from redeeming preferred stock

    80% confidence
  • An announcement on the storage asset sale is expected later in the quarter

    80% confidence
  • Cost management and customer affordability remain central to Spire's strategy, with ongoing investments in system improvements and safety

    80% confidence
  • Spire remains on track to close the acquisition of the Piedmont Tennessee business in calendar Q1 2026

    80% confidence
  • Reaffirmed the company's 2026 adjusted EPS guidance of $5.25 to $5.45 and its 2027 guidance of $5.65 to $5.85, alongside a long-term 5% to 7% adjusted EPS growth target

    80% confidence
  • For the first quarter, we reported adjusted earnings of $108 million or $1.77 per share compared to $81 million or $1.34 per share a year ago

    80% confidence
  • I feel very confident in our ability to do this

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Spire reaffirms 5%–7% EPS growth target and $11.2B capital plan as Tennessee acquisition nears close — Source | Via News | pt.VIA.NEWS